VIDEO: Dual Ang-2, VEGF inhibition provides clinical benefits
Click Here to Manage Email Alerts
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Patricio Schlottmann, MD, discusses dual inhibition of the Ang-2 and VEGF pathways.
Schlottman, of the Organización Médica de Investigación in Buenos Aires, Argentina, said dual inhibition with agents such as faricimab has the potential to provide clinical benefits such as reduced leakage, inflammation and fibrosis regardless of the anti-VEGF dose.
“When you treat a patient aiming for a dual blockage with taking care of the angiopoietin pathway and also blocking the VEGF pathway, you may see more clinical benefit than just treating your patients by blocking the anti-VEGF pathway,” he said.
Collapse
Schlottmann P. Clinical benefits of dual inhibition of Ang-2 and VEGF-A with faricimab. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.
Read more about
Click Here to Manage Email Alerts